Study on Tislelizumab, Pamiparib, and Other Investigational Drugs for People with Advanced Cancers

Sponsor: BeiGene

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT04164199

Provider View

This study is looking at the long-term safety and effectiveness of certain investigational drugs for people with advanced cancers who were part of a previous clinical trial sponsored by BeiGene.

Patient Parameters

Program Overview

This study is designed to continue evaluating the safety and effectiveness of investigational drugs developed by BeiGene for people with advanced cancers. Participants in this study must have been part of a previous BeiGene clinical trial, where they received these investigational drugs. The study aims to see if these treatments continue to be safe and beneficial over a longer period.

Description

In this study, 'study treatment' refers to all investigational drugs being tested. Participants must have been part of a previous BeiGene clinical trial, known as the 'parent study,' where they initially received these investigational drugs. The study will continue to monitor the safety and effectiveness of these treatments over time. Participants will receive their first dose of the study treatment within a specific time frame after their last treatment in the parent study. If there is a planned or unplanned break in treatment, the decision to restart will be made by the study doctor and sponsor. Participants who have not restarted treatment within one year of a planned break must stop treatment. For those only continuing with survival follow-up, they must still be part of a BeiGene-sponsored parent study that includes survival analysis.

Eligibility Criteria

Inclusion Criteria

  • Currently part of a BeiGene-sponsored parent study.
  • Meets the treatment criteria from the parent study.
  • The study doctor believes the participant will continue to benefit from and tolerate the treatments.
  • The first dose of study treatment in this study will be given within the allowed break period from the parent study.
  • For those in survival follow-up only, they must be part of a parent study that plans to analyze survival data.

Exclusion Criteria

  • Stopped all investigational drugs in the parent study due to severe side effects, not following study rules, or withdrawing consent.
  • Have an uncontrolled active infection or recent infection needing IV antibiotics before starting this study.
  • Have a life-threatening illness or medical condition that could affect safety or the study's results.
  • Received any other cancer treatment not allowed in the parent study between the last treatment in the parent study and the first dose in this study.
  • Pregnant or breastfeeding women.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.